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Abstract
We consider the possibility of free receptor (antigen/cytokine) levels rebounding to higher than
the baseline level after one or more applications of an antibody drug using a target-mediated drug
disposition model. Using geometry and dynamical systems analysis, we show that rebound will
occur if and only if the elimination rate of the drug-receptor product is slower than the elimina-
tion rates of the drug and of the receptor. We also analyse the magnitude of rebound through
approximations and simulations and demonstrate that it increases if the drug dose increases or if
the difference between the elimination rate of the drug-receptor product and the minimum of the
elimination rates of the drug and of the receptor increases.
1 Introduction
An interesting property of protein-therapeutic antibody interactions is the potential of the antibody
to change the distribution and clearance pathways of the target protein. This could, in turn, result
in modified concentrations of the target protein in blood and in other organs. For example, binding
and neutralisation of cytokines such as interleukins by blocking/neutralising antibodies causes an
increase in the total levels of the cytokine (Meno-Tetang and Lowe, 2005). This increase is due to the
blockade of the clearance pathways for the cytokine - the large drug-target complex cannot be cleared
through the kidneys and since the complex cannot bind to the target, target-mediated clearance is also
impaired. This complexation process may also have other less well-understood consequences such as
the potential for release of the target from the complex at a later time, and distribution of the target
to tissues and organs due to the longer plasma half-life and potential release of target in the tissues.
In this paper, we will investigate the phenomenon of receptor rebound, i.e., a post-dose rise in re-
ceptor levels to higher than pre-dose (baseline). The increase of the antigen - “antigen rebound” - has
been sparsely studied and only anecdotal reports exist in the literature. For example, rebound symp-
toms have been reported on cessation of anti-tumour necrosis factor (TNF) therapies (Bravo Vergal
et al, 2007) and a corresponding increase in TNF levels have been demonstrated to occur in patients
(Bhatia and Kast, 2007). Similarly, treatment with an anti-IL6 antibody has also been shown to
increase total IL6 activity (Klein et al, 1995) and an increase in tumour size on cessation of VEGF
treatment has also been reported (Cacheux et al, 2008). Apart from the pharmacokinetic (PK) in-
teraction described previously, there might be multiple other reasons for the rebound in target levels
after cessation of treatment with an antibody - an increase in the production rate of the target antigen
due to homeostatic feedback and residual bio-activity of the antibody-target complex, magnified by
the vastly higher levels of the complex are two apparent reasons.
The potential for PK interaction between the target protein and antibody to result in rebound in
free antigen levels is only now being appreciated (Stefanini et al, 2010; Krippendorff and Huisinga,
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Figure 1: The TMDD reaction mechanism
2009). Stefanini et al (2010) use a semi-physiological pharmacokinetic model to hypothesise that the
observed increase in VEGF levels after bevacizumab dosing may be due to the diffusion properties of
the drug, VEGF, and the complex across various tissues. Krippendorff and Huisinga (2009) provide
analytical proof that ligand accumulation occurs when its clearance pathway is blocked, as with a
standard blocking/neutralising antibody approach. However, a systematic evaluation of the physio-
logical conditions and target/antibody PKPD properties that could result in the occurrence of antigen
rebound is not yet available. Such analysis could be critical in designing antibody therapies and dos-
ing regimen that are unlikely to result in antigen rebound and, therefore, maximise the therapeutic
potential of the target.
We consider when a simple protein-antibody interaction results in rebound in protein levels in a
target-mediated drug disposition (TMDD) model, the same one as we considered previously (Aston
et al, 2011) to predict potency. Defining receptor rebound as the post-dose rise in receptor levels
to higher than pre-dose (baseline), we show that, under the assumptions of the basic TMDD model,
rebound will happen if and only if the elimination rate of the target-drug complex is slower than both
the elimination rate of the drug and the elimination rate of the target.
In Section 2, we describe the TMDD model that we will work with and state some important
properties of the model, including global asymptotic stability of the baseline state. In Section 3,
we derive precise conditions on the parameters for the existence and non-existence of rebound in this
model. Section 4 contains a discussion of the results and some conclusions. The proofs of the properties
in Section 2 are presented in the Appendix.
2 The TMDD Model
We consider a one-compartment TMDD model based on the original work by Levy (1994) and Mager
and Jusko (2001) where the drug ligand L binds reversibly with the receptor R to form a receptor-
ligand complex P as shown in Fig. 1. The TMDD model assumes a mechanism-based reaction to
explain the drug-receptor interaction. The parameters of the model are the binding rate constants
kon and koff , the receptor turnover and elimination rates kin and kout, and the elimination rates of the
ligand and complex ke(L) and ke(P). The drug ligand L, receptor R, and receptor-ligand complex P
are all concentrations. The system is assumed to be initially at steady state, into which a single bolus
infusion L0 of the ligand into the central (plasma) compartment is made (represented in Fig. 1 by
‘In’). The differential equations that comprise the mathematical model for this system are given by
dL
dt
= −ke(L)L− konLR+ koffP (1)
dR
dt
= kin − koutR− konLR+ koffP (2)
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dP
dt
= konLR− koffP − ke(P)P (3)
A steady state of this system is given by L = P = 0, R = kin/kout. Adding the bolus injection L0
gives the initial conditions
L(0) = L0, R(0) = R0 =
kin
kout
, P (0) = 0.
We non-dimensionalise these equations (in the same way as used by Peletier and Gabrielsson (2009))
by defining the dimensionless variables
x =
L
L0
, y =
R
R0
, z =
P
R0
, τ = konR0t.
In terms of these non-dimensional quantities, equations (1)–(3) become
x˙ = −k1x− xy + µk2z (4)
y˙ = k3(1− y)−
xy
µ
+ k2z (5)
z˙ =
xy
µ
− (k2 + k4) z (6)
where dot denotes differentiation with respect to τ , with initial conditions
x(0) = 1, y(0) = 1, z(0) = 0,
and the dimensionless parameters are defined by
µ =
R0
L0
, k1 =
ke(L)
konR0
, k2 =
koff
konR0
, k3 =
kin
konR20
=
kout
konR0
, k4 =
ke(P)
konR0
.
Clearly, this choice of non-dimensionalisation requires that kon 6= 0 and kin 6= 0 (so that R0 6= 0). We
note that all parameters must be non-negative due to their physical meaning, and additionally we will
assume that they are in fact all strictly positive. The three variables x, y, and z are related to physical
quantities and so must also be non-negative. After the ligand is added to the system in its baseline
state (corresponding to (x, y, z) = (0, 1, 0)), initially the receptor level decreases, but after a while it
goes up again and returns to its baseline value. Rebound occurs if in the return to the baseline value,
the receptor level increases to values above the baseline.
To support the rebound analysis, in this section we will show that the TMDD model has indeed
an invariant positive octant x, y, z ≥ 0 (as required by their physical meaning); that there is a unique
steady state (the baseline state) in the positive octant, which is a global attractor. We also derive the
local behaviour near the baseline value and show some properties of the total amount of drugs and
the total amount of receptor. The proofs are straightforward and can be found in Appendix A.
Lemma 2.1 [Peletier and Gabrielsson (2012b)] Assuming that kon > 0 and kin > 0, the octant of R
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defined by x, y, z ≥ 0 is invariant under the flow of the equations (4)–(6) and the y-axis is an invariant
line.
In the original variables: the octant L,R,P ≥ 0 is invariant under the flow of the equations (1)–(3)
and the receptor axis is an invariant line, i.e., if there is initially no ligand and product, then this
situation persists for all time.
Next we consider steady state solutions of the non-dimensional equations (4)–(6). We show that
the steady state corresponding to L = P = 0 and R = R0 is the only physically relevant steady state
and is a global attractor.
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Lemma 2.2 In the region of R3 defined by x, y, z ≥ 0, equations (4)–(6) have a unique steady state,
given by
x = 0, y = 1, z = 0. (7)
In the original variables: the baseline state L = P = 0, R = R0, is a unique steady state in the positive
invariant octant L,R,P ≥ 0.
It is possible to prove a global stability result for this steady state. Before we get to this, we
first mention a few other global properties of the dynamical system which can be found for example
in Peletier and Gabrielsson (2012a,b, 2009). The total amount of ligand is given by L + P , hence
its non-dimensional version is u = x + µz. From the differential equation for u(τ), it follows easily
that the total amount of ligand is always decreasing and converges to 0 for time τ going to infinity.
The total amount of receptor is R + P and its non-dimensional version is v = y + z. Initially the
non-dimensional total amount of receptor is v(0) = 1. As shown by Peletier and Gabrielsson (2012b,
2009), if k3 ≥ k4, i.e., the elimination rate of the receptor is faster than or equal to the elimination
rate of the product, then the total amount of receptor stays above or at its initial value. On the other
hand, if the elimination rate of the receptor is slower than or equal to the elimination rate of the
product, then the total amount of receptor stays below or at its initial value.
Lemma 2.3 [Peletier and Gabrielsson (2012a,b, 2009)] Assume that k1 > 0 (ke(L) > 0) or k4 > 0
(ke(P) > 0). Define the non-dimensional form of the total amount of ligand u = x + µz and the
non-dimensional form of the total amount of receptor v = y + z. For all time τ ≥ 0:
• The non-dimensional total amount of ligand u(τ) is monotonic decreasing in time and decays
to 0 for τ → ∞ and hence the total amount of ligand L(t) + P (t) is monotonic decreasing in
time and decays to 0 for t→∞;
• The non-dimensional total amount of receptor v(τ) always stays above, below or at its initial
value v(0) = 1 depending on the relative magnitude of k3 and k4. In particular, for all τ ≥ 0
v(τ)


≤ 1, if k3 < k4;
= 1, if k3 = k4;
≥ 1, if k3 > k4.
In terms of the original variables, the total amount of receptor R(t) + P (t) always stays above,
below or at the baseline value R0 depending on the relative magnitude of the elimination rates
kout(k3) and ke(P)(k4).
A consequence of this lemma is that if it is measured at some moment that the total amount of
receptor is above the baseline level, then the elimination rate of the receptor must be faster than the
elimination rate of the product, i.e., k3 > k4. This is a sufficient and necessary condition.
Corollary 2.4 Assume that ke(L) > 0 (k1 > 0) or ke(P) > 0 (k4 > 0). The elimination rate of the
receptor is faster than the elimination rate of the product if and only if the maximal total receptor level
is larger than the receptor baseline:
max
t>0
(R(t) + P (t)) > R0 ⇔ kout > ke(P) or max
τ>0
v(τ) > 1⇔ k3 > k4.
With the previous observations, we can show the global stability of the asymptotic state.
Theorem 2.5 The steady state (7) of the equations (4)–(6), and hence the baseline state L = P = 0,
R = R0 of equations (1)–(3), is globally asymptotically stable.
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There is an intuitive physical explanation of this result. In the proof, we consider the non-dimensional
form of the total amount of ligand u. Since we are assuming that, after the initial injection, there is
no further input of ligand into the system, but that the ligand and the product are being eliminated
(at rates ke(L) and ke(P) respectively), then clearly the total ligand must decrease over time, as proved.
Once the ligand and product have all been eliminated, the receptor must return to the steady state
value from which it started. The formal proof can be found in Appendix A.
The behaviour close to the globally stable fixed point is dominated by the linearisation about the
fixed point and hence is determined by its eigenvalues and eigenvectors. To find those, we consider
the Jacobian of equations (4)–(6) evaluated at the steady state solution (7)
J0 =


−(k1 + 1) 0 µk2
− 1
µ
−k3 k2
1
µ
0 −(k2 + k4)

 . (8)
The matrix J0 has eigenvalues
λ1 =
1
2
(
−(1 + k1 + k2 + k4) +
√
(1 + k1 + k2 + k4)2 − 4(k1k2 + k1k4 + k4)
)
(9)
=
1
2
(
−(1 + k1 + k2 + k4) +
√
(1 + k1 − k2 − k4)2 + 4k2
)
(10)
λ2 =
1
2
(
−(1 + k1 + k2 + k4)−
√
(1 + k1 + k2 + k4)2 − 4(k1k2 + k1k4 + k4)
)
(11)
=
1
2
(
−(1 + k1 + k2 + k4)−
√
(1 + k1 − k2 − k4)2 + 4k2
)
(12)
λ3 = −k3 (13)
with corresponding eigenvectors
vi = (µ(λi + k3)(k2 + k4 + λi),−(λi + k4), λi + k3) , i = 1, 2, and v3 = (0, 1, 0). (14)
The definition of the eigenvalues gives that λ1 and λ2 are always real (since the term under the square
root is always positive) and that λ2 < λ1. Clearly λ2, λ3 < 0 and, using (9), it is easily verified that
λ1 < 0 also, since all of the non-dimensional constants are positive. Furthermore, if λ1 = −k3 = λ3,
then also v1 = v3. Hence in this case there is a degenerate eigenvalue with geometric multiplicity 1
and algebraic multiplicity 2. These properties of the eigenvalues give the local stability of the steady
state solution (7).
Lemma 2.6 The steady state (7) of the equations (4)–(6), and hence the baseline state L = P = 0,
R = R0 of equations (1)–(3), is linearly asymptotically stable.
Below we give some more bounds on the eigenvalues, depending on the parameters k1–k4. These
bounds play a crucial role in the analysis of the rebound.
Lemma 2.7 For all values of k1, k2, k4 > 0
λ2 < −(k2 + k4) < λ1 < 0. (15)
Lemma 2.8 For all values of k2, k4 > 0, the eigenvalue λ1 is a monotonic decreasing function of k1.
Also,
if k1 > k4 then k4 < −λ1 < k1
if k1 = k4 then − λ1 = k1
if k1 < k4 then k1 < −λ1 < k4
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Figure 2: For k2 and k4 fixed, the (k1, k3) parameter plane is divided up by the lines k1 = k4, k3 = k4
and the curve k3 = −λ1 (λ3 = λ1) for k1 ≥ k4.
3 Rebound
Assuming that the rate constants are strictly positive and that kout  konL0 (hence kon large or L0
large compared to kout), the dynamics of the receptor can be described as follows: After the injection of
the ligand, the receptor initially reduces rapidly (Aston et al, 2011; Peletier and Gabrielsson, 2012a,b)
and then gradually increases on a slower time scale and finally returns back to the steady state.
Rebound occurs if the receptor levels y ever exceeds the steady state value y = 1. We observe that
the existence of rebound is essentially a local property, since we only need to find one point or a small
region where y > 1. However, the non-existence of rebound is a global property, since in this case we
require y ≤ 1 for all t > 0.
To analyse the rebound problem, we use the global properties for the (nondimensional) total
amount of receptor v and the estimates on the eigenvalues from the previous section. We fix k2 and
k4 and divide the (k1, k3) parameter plane up into different regions using the lines k1 = k4, k3 = k4
and the curve k3 = −λ1 (or equivalently λ3 = λ1) for k1 ≥ k4. We noted in the previous section that
λ1 < 0 and so the curve k3 = −λ1 clearly gives positive values of k3. From Lemma 2.8, it follows that
−λ1 is a monotonically increasing function of k1 and so the curve k3 = −λ1 is also a monotonically
increasing function of k1.
The relative position of λ1 and λ3 (= −k3) determines which eigenvalue is the least negative one
and hence dominates the asymptotic behaviour near the fixed point. Lemma 2.8 gives that when
k1 = k4, then λ1 = −k4 and so the curve k3 = −λ1 also passes through the intersection point of the
lines k3 = k4 and k4 = k1. This scenario is shown in Fig. 2. As λ3 = −k3, it follows immediately
that above the curve k3 = −λ1, we have λ3 < λ1 < 0 and below this curve the opposite holds, i.e.
λ1 < λ3 < 0.
Below we analyse each region. For regions I and II, we will show that there is a trapping region
beneath the plane R = R0 such that the solution must stay in this region. Hence the receptor level
cannot exceed the baseline in these regions. For regions III and IV, we consider the asymptotic
approach to the baseline state and show that this approach is always from above the plane R = R0.
This implies that the receptor level will exceed the baseline at some moment in time. So altogether
we prove the following theorem.
Theorem 3.1 Assuming that all parameters k1–k4 are strictly positive, rebound occurs in equations
(4)–(6) if and only if
k4 < k1 and k4 < k3.
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Thus if k2 and k4 are kept fixed, then rebound happens if and only if the ratios k1/k4 and k3/k4 are
both larger than 1.
Converting back to the dimensional parameters, we obtain the following result.
Corollary 3.2 Assume that all rate constants are strictly positive and define rebound as the phe-
nomenon that the receptor level rises above its baseline after an initial decrease due a drug dose, i.e.,
R(t) > R0 for some t > 0. Rebound occurs in equations (1)–(3) if and only if the elimination rate of
the product is slower than the elimination rates of both the ligand and the receptor, or in a formula
ke(P) < ke(L) and ke(P) < kout.
Illustrative example
To illustrate Theorem 3.1 and Corollary 3.2, we simulate the dynamics (time course) of the drug
(ligand), receptor and ligand-receptor complex, see Fig. 3. We fix the parameters koff = 1day
−1 and
kon = 1nM
−1day−1 and set R0 = 1nM; this implies that k2 is fixed with k2 = 1. These values are
motivated by the IgE mAb omalizumab case study by Agoram et al (2007), where koff = 0.9 day
−1,
kon = 0.6 nM
−1day−1 and R0 = 2.7 nM. We have taken the sligthly modified values to facilitate
comparison between those values and the value of the other parameters.
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Figure 3: Time course of the receptor and product levels with ke(P) varying. We have taken ke(L) =
kout = 5day
−1; koff = 1day
−1; kon = 1nM
−1day−1; R0 = 1nM, L0 = 25nM. On the left we have
ke(P) = 1day
−1; on the right ke(P) = 10day
−1. The receptor baseline is denoted by the dashed (red
in colour version) line. On the left, the maximal receptor level Rmax is 1.05 nM, so in this case the
rebound gives a 5% increase above baseline.
We start with fixing ke(L) = kout = 5day
−1, hence k1 = k3 = 5 and investigate changing ke(P) from
inside the rebound region (ke(P) = 1day
−1) to outside (ke(P) = 10day
−1). We take L0 = 25nM. In
both cases, after the drug is added, there is a very fast drop in receptor levels and a rise in product
levels. After this fast initial phase, the product decreases again to zero, while the receptor increases.
On the left (ke(P) = 1day
−1, i.e., inside the rebound region), the receptor goes above the baseline
before returning to the baseline and hence there is a 5% rebound. On the right (ke(P) = 10day
−1),
the receptor returns to its baseline value while staying below it all the time.
The magnitude of the rebound is influenced by the initial amount of drug L0. This is illustrated
in Fig. 4, where we use ke(P) = 1day
−1. The smaller the drug dose L0, the smaller the rebound, but
the efficacy of the drug is also less as can be seen from the increase in the minimal receptor values.
The value of the product elimination rate ke(P) also influences the magnitude of the rebound, the
smaller ke(P), the larger the rebound, with the maximal saturation at ke(P) = 0. This is illustrated in
Fig. 5, where we use L0 = 1000 nM to illustrate that the rebound can become quite significant for a
large dose and small elimination rate of the product ke(P). More details about the magnitude of the
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Figure 4: The drug dose L0 affects the magnitude of rebound and the efficacy of the drug. We use
ke(P) = 1day
−1 and the baseline value is R0 = 1nM.
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Figure 5: The product elimination rate ke(P) affects the magnitude of rebound, but has less effect on
the efficacy of the drug with this dose. We use L0 = 1000nM, the baseline value is R0 = 1nM and
the other constants are ke(L) = kout = 5day
−1.
rebound can be found in Section 3.7.
After presenting this example, we now prove Theorem 3.1 by analysing each region in turn.
3.1 Region I: k3 ≤ k4 (kout ≤ ke(P))
Using the total amount of receptor variable v, we can define a simple trapping region which implies
that rebound cannot occur in this region.
Theorem 3.3 There is no rebound when k3 ≤ k4.
Proof From Lemma 2.3 it follows that in this region the non-dimensional total amount of receptor
satisfies v(τ) ≤ 1 for all τ ≥ 0. As y = v − z and z ≥ 0, this implies immediately that y(τ) ≤ 1 for all
τ ≥ 0. So we can immediately conclude that there is no rebound in this region.
We note that it follows from Lemma 2.3 that when k3 = k4 the flow for the full equations is
restricted to the invariant plane v = y + z = 1. The trajectory in this invariant plane is shown in
Fig. 6. This case was considered in detail by Peletier and Gabrielsson (2009).
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Figure 6: The trajectory starting with y(0) = 1 = x(0), z(0) = 0 in the invariant plane y+z = 1 when
k3 = k4. The starting point (initial condition) is denoted by the solid circle, the asymptotic steady
state by the solid square.
3.2 Region II: k1 ≤ k4 (ke(L) ≤ ke(P))
To analyse region II, we define a trapping region in the (x, y, z)-phase space, with the y = 1 plane
being one boundary, which ensures that no rebound can happen.
Theorem 3.4 Rebound does not occur if k1 ≤ k4.
Proof We define a wedge shaped region in phase space by the conditions
0 ≤ y ≤ 1, µk2z ≤ x ≤ 1− µz, z ≥ 0. (16)
This region, which is shown in Fig. 7, is bounded by the planes
y = 0, y = 1, x = µk2z, x = 1− µz, z = 0. (17)
Note that as the non-dimensional total amount of ligand is given by u = x + µz, the condition
µk2z ≤ x ≤ 1− µz is equivalent to µ(k2 + 1)z ≤ u ≤ 1.
At time τ = 0 the trajectory is at a corner point of this region and we will show that initially it
moves into the wedge. Furthermore, we will show that any trajectory that is inside this wedge cannot
escape, and so the wedge is a trapping region. Since one of the planes that defines this region is y = 1,
it follows that this plane cannot be crossed and so there can be no rebound.
The initial condition of interest, namely I = (x(0), y(0), z(0)) = (1, 1, 0), lies on a corner point of
the region defined by (16) at the intersection of the three planes y = 1, x = 1− µz (u = 1) and z = 0.
Using the notation y˙|I to denote the time derivative of y(t) evaluated at the initial condition I, and
similarly for u˙|I and z˙|I , it is easily verified that
y˙|I = −
1
µ
< 0, u˙|I = −k1 < 0, z˙|I =
1
µ
> 0
and so the trajectory will initially move from the corner point to inside the wedge.
To prove that the wedge is a trapping region, we will show that at the bounding planes the vector
field is pointing inwards or is tangent to the bounding plane. In case of tangencies, we also have to
check that this does not allow the trajectory to escape. To verify that the vector field is pointing
inwards at an edge, we will show that it is pointing in the direction of the inward directed normal to
each of the planes that form the edge. We now consider each of the planes given in (17) in turn.
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Figure 7: The wedge shaped region defined by (16) which is a trapping region for parameter values in
region II. The starting point (initial condition) is denoted by the solid circle, the asymptotic steady
state by the solid square. The vector field is directed inside this wedge, except for the bold (red in
colour version) lines where the vector field is potentially tangent.
• The bounding plane y = 0.
We already considered this plane in Lemma 2.1 when we considered the invariance of the octant
with x, y and z non-negative. We have seen that the vector field on this plane is always pointing
into the octant.
• The bounding plane y = 1.
Using (5) we note that
y˙|y=1 =
−x+ µk2z
µ
.
It follows from the definition of our region in (16) that −x + µk2z ≤ 0. Thus, when x > µk2z,
then y˙|y=1 < 0 and the vector field points into the trapping region on the interior of this plane.
At the edge of the intersection of the planes y = 1 and x = µk2z, the vector field is tangent to
the plane and we will consider this special case below.
• The bounding plane x = µk2z.
The inward pointing normal to this plane is (1, 0,−µk2). For y < 1 and z > 0 the inner product
of the vector field with this normal is
x˙− µk2z˙|x=µk2x = −k1x− (1 + k2)xy + µk2(1 + k2 + k4)z|x=µk2x
= µk2(1 + k2)(1 − y)z + µk2(k4 − k1)z > 0. (18)
as k1 ≤ k4. Hence the vector field at the interior of this plane and at the edges with y = 0 and
x = 1−µz is directed to the inside of the trapping region. At the intersection of this plane with
the planes z = 0 and y = 1 the vector field is tangent and we will consider these cases below.
• The bounding plane x = 1− µz
We have already seen that this is equivalent to u = 1. Using the dynamics for u, we see that the
inner product of the u-vector field with the inward pointing normal at this plane is
− u˙|u=1 = k1u+ µ(k4 − k1)z|u=1 = k1 + µ(k4 − k1)z.
As 0 < k1 ≤ k4 and z ≥ 0, we clearly have −u˙|u=1 > 0 and so the normal derivative is strictly
positive and the vector field is therefore directed inside the trapping region.
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• The bounding plane z = 0
We already considered this plane in Lemma 2.1 when we considered the invariance of the octant
with x, y and z non-negative. We have seen that for x > 0 the vector field on this plane is always
pointing into the octant. The special case of the y-axis is considered below.
In the above discussion, there were several cases where the normal derivative vanished along an
edge of the region, at which two planes meet. We now consider these edges in more detail. Before
doing this however, we note that the corner point of the region defined by z = 0, y = 1 is the final
steady state that all trajectories converge to (by Theorem 2.5) and at this point, the derivatives of all
three variables vanish. So when we consider the various edges, we can exclude this corner point from
consideration. The two edges that we have to consider are as follows:
• The edge x = µz, y = 1.
When k1 < k4, we see from (18) that at this edge the vector field is tangent to the plane y = 1
and points inwards along the plane x = µx if z > 0. Thus, the vector field is directed away from
the edge and so no trajectory can approach this edge.
If k1 = k4, we see that the vector field is tangent to the edge as it is tangent to both planes. So
this edge is invariant under the flow, with the trajectory converging to the steady state along
this line. Thus, it is not possible for a trajectory to escape the trapping region along this line.
• The edge x = 0, z = 0, hence the y-axis.
We have already seen that this axis is invariant under the flow (Lemma 2.1), with the trajectory
moving up the axis towards the steady state at y = 1. Thus, this edge cannot be crossed.
Combining all of the above results, it follows that the vector field at the interior of the bounding
planes is always pointing into the wedge and that at the edges it is either pointing inwards or if it is
tangent to an edge, an orbit cannot approach this edge. So we can conclude that if a trajectory starts
in the wedge shaped region defined by (16), then it cannot escape from this region, and so the wedge
is a trapping region for the flow.
As mentioned previously, one of the boundary planes of the trapping region (16) is y = 1 and so
there can be no rebound.
Clearly there is some overlap between this region and region I, but the conclusion that rebound
does not occur is consistent in the overlapping region.
3.3 Region III: k1 > k4 (ke(L) > ke(P)), k3 > −λ1
We show that there is rebound in this case by considering the linearised manifold from the steady
state in the direction associated with the slowest converging eigenvalue which is λ1.
Theorem 3.5 Rebound occurs if k1 > k4 and k3 > −λ1.
Proof It is clear from (9) and (11) that λ2 < λ1 and since we are also assuming that −λ3 = k3 > −λ1,
then λ3 < λ1 and so the eigenvalue that is closest to zero is λ1, which has corresponding eigenvector
v1 (see (14)). The one-dimensional linearised manifold from the steady state in the direction of the
eigenvector v1 is therefore
 xy
z

 =

 01
0

+ α

 µ(k2 + k4 + λ1)(λ1 + k3)−(λ1 + k4)
λ1 + k3

 . (19)
We are only interested in the positive octant, hence x and z must be non-negative quantities. This will
only occur if α ≥ 0, since the first and third entries in the eigenvector are positive, using Lemma 2.7
and since λ1 + k3 > 0.
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Figure 8: A sketch of the two-dimensional manifold in a neighbourhood of the steady state (indicated
by the solid square) which is tangent to the plane generated by the eigenvectors v2 and v3.
From Lemma 2.8, we see that along this manifold, y exceeds the steady state value y = 1 since
k1 > k4. Now generically, almost all trajectories will approach the steady state tangent to the linearised
manifold (19), since this is associated with the eigenvalue λ1 which is closest to zero. If this is the
case then y must approach the steady state value y = 1 from above, so that rebound occurs.
Of course, it is always possible that the generic condition stated above does not hold for some
initial conditions. If this were the case, then the trajectory would approach the steady state tangent
to one of the other linearised manifolds generated by the eigenvectors v2 or v3. We now show that this
is not possible.
A given trajectory would not approach the steady state tangent to the linearised manifold (19) only
if the initial condition happened to lie on the global two-dimensional stable manifold which is tangent to
the plane generated by the eigenvectors v2 and v3 at the steady state. Finding global two-dimensional
manifolds is not usually possible, and so this condition would seem difficult to check. However, we
will show that the two-dimensional tangent plane associated with the eigenvector directions v2 and v3
lies outside the positive octant, except for the y-axis. This will allow us to infer results concerning the
global two-dimensional manifold from this.
We note from Lemma 2.7 that the first entry in the eigenvector v2 is negative and so the first and
third entries of the eigenvector have opposite sign. The one-dimensional linearised manifold associated
with this eigenvector can be obtained by replacing λ1 with λ2 in (19). Since the first and third entries
of v2 are of opposite sign, it follows that along the linearised manifold, we will have xz ≤ 0 so that
precisely one of the variables x and z is always negative (except at the steady state). Clearly, with the
exception of the steady state itself, this manifold is outside the phase space for our equations, since
we require all the variables to be non-negative.
We note that the linearised manifold associated with the eigenvector v3 is simply the y-axis. As
noted in Lemma 2.1, the y-axis is in fact invariant under the flow and so this axis is also the global
one-dimensional stable manifold associated with the eigenvalue λ3.
We can now describe the form of the global two-dimensional stable manifold associated with the
eigenvectors v2 and v3. Since the y-axis is the global one-dimensional stable manifold in the direction of
v3 and the linearised manifold in the v2 direction has xz ≤ 0, it follows that the global two-dimensional
stable manifold will include the y-axis, but that in the neighbourhood of this axis, the manifold will be
outside of the phase space of the problem (see Fig. 8). Thus, the only physically relevant trajectories
that approach the steady state on this manifold are the trajectories on the y-axis. Our initial condition
is not on the y-axis and so our trajectory must approach the steady state tangent to the eigenvector
v1. Thus the condition k1 > k4 is sufficient to ensure that rebound does occur.
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3.4 Region IV: k4 < k3 < −λ1 (kout > ke(P))
The second inequality in these conditions is equivalent to λ1 < λ3, hence λ3 is the slowest eigenvalue.
As in the previous region, we will show that there is rebound in this case by considering the manifold
associated with this slowest eigenvalue.
Theorem 3.6 Rebound occurs if k4 < k3 < −λ1.
Proof Our assumptions imply that λ1 < −k3 = λ3 and so the eigenvalue closest to zero in this case is
λ3. Thus, most orbits will approach the steady state tangent to the y-axis. With regard to rebound,
the important question is whether on this axis they approach the point y = 1 from above or from
below.
From Lemma 2.3, we see that in this region we have v(t) ≥ 1 for all t ≥ 0. The plane v = 1 meets
the y-axis at the steady state y = 1, x = z = 0. Clearly the only part of the y-axis that is above the
plane v = 1 consists of the part where y > 1 (as z = 0 at the y-axis). Thus, when k3 > k4, generically
almost all orbits will approach y = 1 from above, resulting in rebound.
As in the proof of Theorem 3.5, we must also consider the possibility that an orbit might ap-
proach tangent to one of the other eigenvectors for a particular choice of parameter values. The
one-dimensional linearised manifold in the direction of the eigenvector v2 is outside of the phase space
for the problem, using a similar proof to that given in the proof of Theorem 3.5, and so it is not pos-
sible for a physically relevant trajectory to approach the steady state tangent to this one-dimensional
manifold.
The remaining case is related to the eigenvector v1. The one-dimensional linearised manifold in
the direction of v1 is given by (19) and so we must consider whether it is possible that a trajectory
could approach the steady state tangent to this manifold. From (19), we note that along this linearised
manifold we have
v = y + z = 1− α(λ1 + k4) + α(λ1 + k3)
= 1 + α(k3 − k4). (20)
In this case, we must restrict to α ≤ 0 to ensure that x, z ≥ 0. We also note from the assumptions
of the Theorem that k3 − k4 > 0, and so we see that along this linearised manifold we have v < 1
for α < 0. Since we have already noted that our trajectory must satisfy v ≥ 1 in this case, clearly
it cannot approach the steady state tangent to this one-dimensional linearised manifold, since it lies
below the v = 1 plane.
Thus, we conclude that all trajectories must approach the steady state tangent to the y-axis and
from above, and so rebound must occur under these conditions.
3.5 The boundary between regions III and IV (λ1 = λ3)
The boundary between the regions III and IV is the line λ3 = λ1 (or equivalently λ1 + k3 = 0), with
k1 > k4 and k3 > k4. Along this curve, the Jacobian matrix (8) has a repeated eigenvalue (λ1 = λ3)
and the eigenvector v1 coincides with the eigenvector v3 (see (14)), and so there is only one eigenvector
in this case, as would be expected for a multiple eigenvalue. As the curve λ3 = λ1 is crossed from
above to below (with k4 < k1), i.e. from region III to region IV, the trajectory initially approaches
the steady state tangent to the eigenvector v1. As the curve λ1 = λ3 is reached, the eigenvectors
v1 and v3 coincide and are parallel to the y-axis. Once the curve has been crossed the trajectories
then approach the steady state tangent to v3, and so there is a smooth transfer between these two
cases as the line is crossed. In each open region, we used an asymptotic argument to conclude that
the trajectory with the given initial condition has to approach via the eigenvector associated with the
least negative eigenvalue and from above the plane y = 1. We have not yet considered the boundary,
although it can be expected on grounds of continuity that the scenario will be very similar. This is
indeed the case as is shown below.
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Theorem 3.7 Rebound occurs if k4 < k3 = −λ1.
Proof As λ1 = λ3 and λ2 < λ1, the least negative eigenvalue is a double one and hence a two-
dimensional stable manifold is associated with it. The linearised two-dimensional manifold can be
expressed in terms of the eigenvector (v1 = v3 = (0, 1, 0)) and the generalised eigenvector vg, which is
defined by
(J0 − λ1I)vg = v1.
The solution of this equation is
vg = (µk2, 0, λ1 + k1 + 1) /[k2(λ1 + k1)].
Note that λ1 + k1 > 0 as k1 > k4 (see Lemma 2.8) and so this vector is well-defined and points into
the positive octant of the phase space.
The solutions on the linearised manifold are linear combinations of eλ1t(vg+tv1) and e
λ1tv1 (Jordan
and Smith, 2007). Asymptotically all solutions in the two-dimensional linearised manifold align with
the eigenvector v1 direction, which is the y-axis. This property carries over to all solutions on the
global nonlinear two-dimensional manifold associated with the repeated eigenvalue λ1 = λ3. The
eigenvalue λ2 is more negative than λ1 and we have seen in the previous two sections that its stable
one-dimensional manifold is outside the positive octant (except for the steady state). So all trajectories
from inside the octant will asymptotically align with the y-axis.
Since we are assuming that k3 > k4, we see from Lemma 2.3 that the total receptor v satisfies
v(τ) ≥ 1 for all τ ≥ 0. As in the proof of Theorem 3.6, the only part of the y-axis that is above the
plane v = 1 is the part with y > 1, and so all orbits must approach the steady state y = 1 from above,
resulting in rebound in this case as claimed.
3.6 Multiple dosing
Thus far, we have considered only a single bolus injection. We now consider the possibility of rebound
when there are multiple bolus doses. The rebound phenomenon that we have been studying occurs as
the receptor level is returning to its steady state. It might be conjectured that our rebound results also
hold whether there is a single bolus injection initially, or multiple bolus injections. Clearly, multiple
doses will keep the receptor level low for a longer period, but the process of returning to the steady
state could well be similar to the single dose case. We now show that this is indeed the case.
Theorem 3.8 If the system (1)–(3) is subject to an arbitrary (but finite) number of bolus doses of the
ligand of arbitrary (but finite) amounts at any desired points in time, then the conditions of Corollary
3.2 still apply for determining whether or not rebound will occur.
Proof In terms of the non-dimensional equations (4)–(6), an additional injection L1 of the ligand at
a time t1 > 0 corresponds to a discontinuous increase in the variable x such that
x(t+1 ) = x(t
−
1 ) +
L1
L0
.
Further bolus doses would correspond to additional discontinuous increases in x. We now consider
each of the Theorems in the four regions in turn and consider the effect of such changes in x on the
result.
In Theorem 3.3 (region I), the proof that there is no rebound lies in the fact that the trajectory
always has v ≤ 1. The changes made to x from the additional doses have no effect on the value of
v = y + z, and so the trajectory will continue to satisfy the condition v ≤ 1 when there are multiple
doses, and so there is again no rebound.
In the proof of Theorem 3.4 (region II), an additional dose may have the effect of moving the
trajectory outside of the trapping region that we defined. In particular, the variable u = x+ µz may
14
exceed the boundary value of u = 1 when x is increased. However, we note that we can increase the
size of the trapping region by moving this boundary plane to u = c for any c > 1. In this case, we
have
u˙|u=c = −k1c− µ(k4 − k1)z
and since in this case we are assuming that k1 ≤ k4 and z ≥ 0, we still have u˙|u=c < 0 for any c > 1.
Thus, provided that the total amount of dosing is finite, we can always find a value of c such that the
trajectory with multiple dosing stays inside the trapping region and so, as previously, there can be no
rebound in this case.
In Theorems 3.5, 3.6 and 3.7 (regions III, IV and their boundary), the existence of rebound is
proved by considering the approach to the steady state in the phase space. The additional doses have
no effect on this process. An additional argument used is the fact that the trajectory satisfies v ≥ 1.
As in the previous case, additional doses have no effect on v. So altogether we can conclude that the
results still hold and that there will be rebound in this region.
3.7 Magnitude of the rebound
As can be seen from the diagrams in Figs 3–5 for the example in the introduction of this section, the
dynamics has two phases. An initial fast phase in which the receptor levels drop very sharply and
a more gradual phase in which the receptor levels recover and rebound if the elimination rate of the
product is small. To see these phases more clearly, we rewrite the system in terms of the variables
u = x+µz, the non-dimensional form of the total amount of ligand, and v = y+z, the non-dimensional
form of the total amount of receptor. We introduced these variables previously in Lemma 2.3. In these
variables, together with y, the equations (4)-(6) become
u˙ = −k1 u+ µ (k1 − k4) (v − y) (21)
v˙ = k3 (1− y)− k4 (v − y) (22)
µy˙ = −y (u− µ(v − y)) + µk3 (1− y) + µk2 (v − y) (23)
Since µ = R0/L0 represents the baseline receptor concentration divided by the initial drug concen-
tration, this is usually quite a small number. As shown by Aston et al (2011), by going to the fast
time τ = t/µ, initially the total drug concentration u and the total receptor concentration v will
stay approximately constant, while the receptor quickly adapts such that the right hand side of the y˙
equation nearly vanishes, i.e.,
−y (u− µ(v − y)) + µk3 (1− y) + µk2 (v − y) = O(µ). (24)
More about this fast-slow process and the minimal receptor value, can be found in the paper by Aston
et al (2011).
We are interested in the maximal y value, so we would like to keep the y variable in our slow
system. The slow manifold relation (24) suggests the following coordinate transformation
y = µY and u =
1
Y
(k2v + k3) + µw,
leading to the equations
µw˙ = −
1
Y
(wF1(v, µY )− (v − µY ) (F1(v, µY )− F2(µY )) + F3(v)) (25)
v˙ = k3 (1− µY )− k4 (v − µY ) (26)
Y˙ = −Y (w − v + µY + k2 + k3) (27)
with F1(v, y) = k1y+k2v+k3, F2(y) = k2(k3−k4)+k4y and F3(v) = k2v(k1+k2)+k3(k1+2k2+k3).
In these equations, it is now the w variable that changes rapidly, while v and Y change more slowly for
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Figure 9: Projection of the heteroclinic orbit and solutions curves for various small values of µ = R0
L0
.
We use R0 = 1, k2 = 1 = k4 and k1 = k3 = 5.
small µ. In the fast time variable τ = t/µ, there is an invariant, normally hyperbolic two dimensional
manifold at µ = 0, given by w = v − F2(0)v+F3(v)
F1(v,0)
. Thus for µ small and Y bounded (i.e., y small),
Fenichel’s theory (Fenichel, 1979) gives the existence of a two-dimensional invariant manifold
w = Wman(v, µY ;µ) = v − µY −
F2(µY )(v − µY ) + F3(v)
F1(v, µY )
+O(µ).
As F1(v, µY ) > k3 for all µY and v, it follows immediately that this invariant manifold is attracting for
Y > 0. In Section 2 it is shown that the system has a global attractor which, in the new coordinates,
is given by (w, v, µY ) = (−k2 − k3, 1, 1). Thus by continuing the flow of the invariant manifold
w = Wman(v, µY ;µ) it will include this attractor.
Furthermore, in the (w, v, y) dynamics there is another steady state at
(w, v, µY ) =
(
Wman
(
k3
k4
, 0;µ
)
,
k3
k4
, 0
)
(28)
which is on the invariant manifold (note that in the original (x, y, z) coordinates this point corresponds
to x ∼ ∞ (as u ∼ 1
y
→ ∞)). The eigenvalues of the Jacobian evaluated at this steady state on the
invariant manifold are λ1 = k1 and λ2 = −k4 and so it is a saddle point. Hence the heteroclinic
connection between this steady state and the global attractor is on the (extended) invariant manifold
too.
Remark We note that (27) implies that the plane at Y = 0 is invariant, but on the other hand (25)
is singular at Y = 0. So for µ 6= 0, the steady state (28) is the only intersection of the invariant
manifold with the plane Y = 0. For all other points on the invariant manifold Y > 0. For µ = 0, the
curve Y = 0, w = Wman(v, 0; 0) is on the invariant manifold and this curve is the stable manifold of
the fixed point (28).
The invariant manifold cannot be crossed by any solution, thus if a solution is initially under the
manifold, it will stay under the manifold for all time. At the end of the fast phase, our solution will
have approached the invariant manifold (from below) near the point (w, v, µY ) = Wman(1, 0; 0) ≈
(−(k1 + k2 + k3 − 1 +
k2(k3−k4)
k2+k3
), 1, 0). In the (v, y) projection, this point is to the left of the fixed
point as k3 > k4 (a necessary condition for rebound). The invariant manifold is attracting, so it can
be expected that in the (v, y) projection the orbit will stay under the heteroclinic connection. This
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Figure 10: The maximum value of y on the heteroclinic orbit in the rebound region with R0 = 1 and
k2 = 1 = k4. The line in the k1–k3 plane is the boundary between regions III and IV. Region IV is
near to the k1 axis.
is illustrated in Fig. 9. Then the maximal y value on the heteroclinic orbit is an upper bound on
the magnitude of the rebound. In Fig. 10, we computed this upper bound for ke(P)(= k4) = 1 and
ke(P)(= k1) and kout(= k3) varying in regions III and IV. The surface is smooth near this boundary and
crossing the boundary seems to have little significant effect on the maximum. Clearly, the magnitude
of the rebound increases if either the elimination rate of the ligand (ke(L) ≡ k1) is increased or the
elimination rate of the free receptor (kout ≡ k3) is increased.
We note that the highest value on the surface shown in Fig. 10 corresponds to the parameter
values considered in our earlier example. The maximum rebound according to this upper bound is
ymax = 1.18798. It can be seen from the table in Fig. 4 that the magnitude of rebound is increasing
as L0 increases towards this upper bound.
4 Discussion and Conclusions
We have considered in detail a simple TMDD model and have derived precise conditions for the
existence or non-existence of antigen rebound under circumstances described by the model. The key
result (Theorem 3.1 and Corollary 3.2) states that rebound occurs if and only if the elimination rate
of the product is slower than the elimination rates of both the ligand and the receptor, for one or more
bolus doses. To explain this intuitively, we note that the initial fast phase after the administration
of the ligand corresponds mainly to the reaction between the ligand and the receptor which forms
the product. However, if the resulting product is not removed quickly enough, then the reverse
reaction will occur where the product dissociates back into its component parts. Thus, the receptor
is being replenished at a rate kin and additional receptor is being formed from this dissociation. The
combination of these effects gives the excess receptor which results in the rebound. A further corollary
of these results is that the rate of reaction between the ligand and the receptor and the rate of
dissociation of the product play no role in determining the existence or non-existence of rebound in
this model.
In the development of antibodies, it can be a problem to monitor the free receptor (antigen,
cytokines) levels. The total amount of receptor is often used as a substitute to measure drug ac-
tivity (Haringman et al, 2006; Vugmeister et al, 2009), although Ait-Oudhia et al (2012) recently
showed how free antigen levels could be derived from a model and linked to clinical outcomes. From
Corollary 2.4, it can be seen that if the total receptor level gets above the receptor baseline then the
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elimination rate of the receptor must be faster than the elimination rate of the product. Thus total
receptor level getting above the receptor baseline is a necessary condition for rebound, but it is not
sufficient. If the elimination rate of the drug is slower than the elimination rate of the product, there
will be no antigen rebound, even though the total receptor level is always above or at baseline if the
elimination rate of the receptor is faster than the elimination rate of the product.
We have also analysed the magnitude of antigen rebound in the simple TMDD model. For a given
baseline receptor level, larger antigen rebound is predicted for higher doses of the administered ligand
or for slower complex elimination rates. This is intuitive, since with higher doses larger amounts
of complexes are formed and with longer complex elimination times, there is a higher concentration
gradient driving dissociation of the complex. Another observation is that the faster the elimination
rate of either the ligand (ke(L)) or the receptor (kout), the larger the rebound.
Reported data indicate that for most blocking/neutralising biologics, mostly monoclonal antibod-
ies, the complex is eliminated at the same rate as the antibody (e.g. Meno-Tetang and Lowe (2005)).
However, in some cases, the complex is eliminated faster than the antibody due to factors such as
interference of antigen binding on antibody salvage mechanisms (e.g. Lowe et al (2009); Chan et al
(2009)). There are very few examples of the complex being eliminated slower than both ligand and
receptor. One such example is that of an anti-IL13 antibody (Vugmeister et al, 2009), where the
condition required for antigen rebound was observed in naive cynomolgus monkeys. Another report
(Munafo et al, 2007) also suggests that the required condition may have been satisfied. However,
in both these cases, no rebound was reported in preclinical or clinical trials. It is possible that the
rebound, if it did occur, might have been of too small a magnitude to be of any consequence. Based
on our simulations with the model reported by Vugmeister et al (2009), the magnitude of rebound
would have been over 250%. However, we suspect a typographical error in the reported model. Us-
ing the corrected model (where we replaced a term involving the difference of the concentration of
free IL-13 minus the concentrations of bound IL-13, i.e. CIL−13 − CAb−(IL−13) − CAb−(IL−13)2 , by the
concentration of free IL-13 CIL−13), the magnitude of the rebound is less than 1% and the graphs are
similar to the ones given in the paper by Vugmeister et al (2009). Binding to cell-surface receptors
typically results in accelerated turnover of the antibody and the complex (e.g. Ng et al (2006); Wang
et al (2012)). There are no reports known to the authors where binding to cell-surface receptor leads
to formation of complexes that are cleared slower than the receptor or ligand. The rarity, experimental
detectability and potential lack of clinical consequences, as detailed above might be one of the reasons
this phenomenon has not received a lot of attention so far. However, it should be noted that many
smaller biologic modalities such as Fab fragments and Fc fusion proteins have much shorter half-lives
than mAbs (∼1–2 days for example). Therefore, binding to antigen has the potential to create a
complex with longer half-life than either receptor or ligand. Furthermore, many preclinical studies are
typically done with Fabs and scFvs, so the required conditions for rebound may occur in those cases.
Our analysis can provide a framework for predicting rebound and/or interpreting unexpected results
under these conditions.
The analysis presented above is limited by the fact that the simplest system of interaction between a
ligand and a receptor is described and analysed for rebound. Other factors such as tissue re-distribution
and homeostatic feedback may play an important and potentially greater role in antigen rebound and
are beyond the scope of this analysis. They will be considered in our subsequent paper (Aston et al,
2012), in which we adapt this model to allow feedback in the production of the target protein, so
that when the protein levels are reduced, the production rate increases. In spite of its limitations,
the analysis presented above has highlighted the important factors that govern occurrence of antigen
rebound in such systems and the need to understand these interactions prior to design of therapies
targeting them. The analysis has also highlighted the value added by fundamental quantitative analysis
in the design of biologic therapies.
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A Proofs of Invariance and Stability Results
Proof of Lemma 2.1 The phase space is bounded by the three planes x = 0, y = 0 and z = 0. If
the vector field given by the equations (4)–(6) at these planes is directed inside or is tangent to the
octant, then the given region is invariant (Smith, 1995).
Taking the inner product of the vector field with the inward pointing normal at the plane x = 0,
we see from (4) that
x˙|x=0 = µk2z
and so x˙|x=0 ≥ 0 when z ≥ 0. Hence the vector field is directed inside the octant at the plane x = 0.
Similarly, from (5), we obtain
y˙|y=0 = k3 + k2z
and so y˙|y=0 > 0 when z ≥ 0. In the same vein, from (6), we obtain
z˙|z=0 =
xy
µ
and so z˙|z=0 ≥ 0 when x, y ≥ 0.
Note that at the x-axis (y = z = 0), the vector field is tangent to the plane z = 0, and is pointing
inwards as y˙|y=z=0 = k3. At the y-axis (x = z = 0), we have x˙ = 0 and z˙ = 0, hence x and z will stay
zero for all time and the y-axis is invariant. On the y-axis, y˙ > 0 if y < 1 and y˙ < 0 is y > 1. Hence
all orbits on the y-axis tend to the stable steady state at y = 1.
Thus, we can conclude that any trajectory with x(0), y(0), z(0) ≥ 0 must satisfy x(t), y(t), z(t) ≥ 0
for all t > 0.
Proof of Lemma 2.2 There are two steady state solutions of equations (4)–(6), one of which is given
by (7). The other solution is not in our phase space, and hence is not physically relevant, as the values
of x and y are negative.
Proof of Corollary 2.4 By negating Lemma 2.3, it follows immediately that if the maximal v(τ)
value is above 1, then k3 > k4. And Lemma 2.3 implies that if k3 > k4, then v(τ) ≥ 1 for all τ .
We only have to show that v(τ) cannot be equal to 1 for all time. This follows immediately with a
contradiction argument. Assume that k3 > k4 and v(τ) = 1 for all τ ≥ 1. Then the v-dynamics (22)
gives for all τ ≥ 0 that 0 = (k3 − k4)z, hence z(τ) = 0. Then (6) implies that 0 =
xy
µ
for all τ ≥ 0.
However at τ = 0, we have xy
µ
= 1
µ
. This is a contradiction, thus the assumption that v ≡ 1 is false.
Proof of Theorem 2.5 In Lemma 2.3 we have shown that limτ→∞ u(τ) = 0. Since u = x+ µz and
x and z are non-negative functions, we conclude that limτ→∞ x(τ) = limt→∞ z(t) = 0 also. Hence,
every trajectory will converge to a neighbourhood of the y-axis. We have also seen in Lemma 2.1 that
the y-axis is invariant and that on this axis, all orbits tend to the stable steady state at y = 1. So
intuitively it is clear that all trajectories will converge to the steady state (7) as τ →∞. To make this
formal, we consider the y-dynamics in a neighbourhood of the y-axis.
Let ε > 0. Since limτ→∞ x(τ) = limτ→∞ z(τ) = 0, then there is some T > 0 such that for τ > T ,
we have
0 ≤ x(τ) ≤ εµk3 and 0 ≤ z(τ) ≤ εk3/k2.
Thus with (5), we get for τ > T ,
k3 [1− (1 + ε)y)] ≤ y˙ ≤ k3 [1 + ε− y] .
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In other words, d
dτ
[
ek3(1+ε)τ
(
y − 11+ε
)]
≥ 0 and d
dτ
[
ek3τ (y − (1 + ε))
]
≤ 0 and we can conclude that
for τ ≥ T
−
ε
1 + ε
+ e−k3(1+ε)(τ−T )
(
y(T )−
1
1 + ε
)
≤ y(τ)− 1 ≤ ε+ e−k3(τ−T ) (y(T )− (1 + ε))
Hence by choosing ε sufficiently small and for all τ > T sufficiently large, we can make |y(τ) − 1|
arbitrarily small. So we conclude that y(τ)→ 1 for τ →∞.
Proof of Lemma 2.7 This observation follows quickly from the expressions for the eigenvalues λ1
and λ2. Indeed, from (10) we find that
k2 + k4 + λ1 =
1
2
(
−(1 + k1 − k2 − k4) +
√
(1 + k1 − k2 − k4)2 + 4k2
)
> 0,
since k2 > 0 and hence the square root term is larger than the magnitude of the first term. Similarly,
using (12) we get
k2 + k4 + λ2 =
1
2
(
−(1 + k1 − k2 − k4)−
√
(1 + k1 − k2 − k4)2 + 4k2
)
< 0.
Proof of Lemma 2.8 Let k2, k4 > 0 be fixed. Differentiating the expression for λ1, (10), with respect
to k1 gives
∂λ1
∂k1
= −
1
2
(
1−
1 + k1 − k2 − k4√
(1 + k1 − k2 − k4)2 + 4k2
)
.
The second term in the brackets is less than one in modulus (since k2 > 0), and so this derivative is
always negative. Thus, λ1 is a monotonically decreasing function of k1.
To derive the stated bounds on −λ1 that involve k4, we note that from (9) we have
λ1 + k4 =
1
2
(
−(1 + k1 + k2 − k4) +
√
(1 + k1 + k2 − k4)2 + 4(k4 − k1)k2
)
. (29)
When k1 < k4, the square root term in (29) always dominates the first term, and so λ1 + k4 > 0.
When k1 = k4, we have
λ1 + k4 =
1
2
(−(1 + k2) + |1 + k2|) = 0.
Finally, when k1 > k4, we note that 1 + k1 + k2 − k4 > 0 and in this case, the first term in (29)
dominates the square root term and so we find that λ1 + k4 < 0.
Similarly, for the bounds on −λ1 involving k1, from (9) we obtain
λ1 + k1 =
1
2
(
−(1− k1 + k2 + k4) +
√
(1− k1 + k2 + k4)2 + 4(k1 − k4)
)
.
The sign of λ+ k1 is then obtained in the same way as for the sign of λ+ k4 above.
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